Rapamycin is the longevity intervention with the strongest mechanistic basis and the most consistent rodent data. Human evidence for healthspan-specific benefits is limited to immune markers and safety; lifespan outcomes are decades away from being measured.
Does rapamycin extend lifespan?
Rodent data
The NIH Interventions Testing Program (ITP) Harrison, Strong, Sharp et al. (ITP) 2009 has run the most robust rapamycin trials in mice (UM-HET3 heterogeneous strain):
- Median lifespan extension ~10-14% in males, ~15-23% in females.
- Works when started mid-life (9 months), even larger effect when started early.
- Intermittent administration produces similar lifespan effects with fewer side effects vs daily.
- Mechanism: mTORC1 inhibition → increased autophagy + reduced protein synthesis + altered glucose metabolism.
Human data
Mannick 2018 (n=264, Science Translational Medicine): elderly adults received 6 weeks of everolimus (rapamycin analog) + BNT162b1 influenza vaccine ( Mannick et al. 2018, n=264 ). Result: improved seroconversion vs placebo + reduced respiratory infections for 12 months post-treatment. Immune rejuvenation signal.
PEARL trial (Blagosklonny 2023): healthy adults, rapamycin 5-10 mg weekly for 48 weeks. Safety demonstrated. No lifespan endpoint.
No completed trial has measured hard longevity outcomes (mortality, healthspan-years) in humans on rapamycin. Probably never will directly; proxies (frailty indices, methylation age, function markers) will be the available evidence.
For context: Mandsager 2018 (n=122,007) showed each 1-MET improvement in cardiorespiratory fitness reduced all-cause mortality ~11% ( Mandsager et al. 2018, n=122007 ) , a larger effect per unit of intervention than any pharmacologic longevity candidate currently under trial. Rapamycin is layered on top of fitness, not substituted for it.
How do you cycle rapamycin?
Among off-label users in the biohacker community (Brian Kennedy cohort, Peter Attia's protocol, Rapamycin Longevity Trial n=1 community):
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Starter | 2 mg | weekly, 4-6 weeks | Assess tolerability (mouth sores, GI, lipids) |
| Standard (Attia-style) | 5 mg | weekly, continuous | Most reported real-world dose |
| Cyclic (some Kennedy group) | 6 mg | 1 week on / 2 weeks off | Reduces glucose + lipid impact |
| High-frequency deload | 6 mg x2/week | for 6 weeks, off for 6 | Closer to ITP mouse protocol translation |
| Pulse (Lloyd Klickstein protocol) | 10-20 mg | single dose every 1-3 months | Emerging; immune benefit without chronic exposure |
Dose is in oral sirolimus tablets (the pharmaceutical compound is the same as the pharmaceutical transplant-immunosuppression formulation; longevity doses are substantially lower than immunosuppressive doses).
What are the side effects of rapamycin?
Common:
- Mouth sores / stomatitis: most common. Dose-dependent. Can be mitigated by rinsing with saltwater + careful oral hygiene.
- Mild lipid elevation (LDL + triglycerides). Monitor annually.
- Mild glucose elevation. Monitor annually.
- Delayed wound healing. Hold rapamycin 1-2 weeks before and after surgery.
Less common:
- GI disturbance.
- Peripheral edema.
- Anemia or thrombocytopenia (rare at low weekly doses).
Rare but real:
- Interstitial pneumonitis. Stop immediately if new-onset cough + dyspnea.
- Infections (doses this low rarely cause meaningful immune suppression, but the risk is non-zero).
Monitoring:
- Baseline CBC + CMP + lipid + A1c.
- Repeat at 3, 6, 12 months.
- Hold during acute infection.
- Reconsider if lipid or glucose shift is significant and lifestyle-resistant.
Who should not take rapamycin?
- Anyone with active infection or recent surgery.
- Immunosuppressed patients (HIV uncontrolled, post-transplant on other immunosuppressants).
- Trying to conceive (both men and women): animal teratogenicity concerns.
- Chronic kidney disease stage 3+.
- Uncontrolled diabetes.
Interactions to check
- Statins: dose-adjust needed (shared CYP3A4 metabolism).
- Grapefruit juice: increases rapamycin AUC substantially. Avoid on dosing day.
- Erythromycin, clarithromycin, ketoconazole: raise rapamycin levels.
- Vaccines: some clinicians hold rapamycin around vaccination; others time rapamycin to potentiate response per Mannick.
The honest case
For: Strongest mechanistic support of any human longevity intervention. Mouse data is consistent. Safety in healthy adults is reasonably demonstrated at off-label doses.
Against: No human lifespan outcome data. Side effects (lipid, glucose, mucositis) are real. Requires prescription access. Cost ~$150-400/month depending on source.
Counter-view
Matt Kaeberlein and David Sabatini endorse rapamycin's mechanistic case but are cautious on dose translation from rodent to human. Peter Attia uses it personally and recommends it to selected patients; his position is well-argued but more aggressive than mainstream geroscience. Nir Barzilai is more measured; TAME-metformin first, rapamycin case stronger but clinical infrastructure not ready.
